Maria Decastro, DO
Neurology · Brandon, FLNPI 1558326470
Payments from drug & device makers
Across 60 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$179
- AbbVie$166
- Teva Pharmaceuticals USA, Inc.$157
- Lilly USA, LLC$126
- Amgen$121
- Globus Medical$110
- plus $508 from 16 others
What the payments were for
- Food & beverage$1,27693%
- Education$917%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 9 | $179 |
| AbbVie(2 entities) | 8 | $166 |
| Teva Pharmaceuticals USA, Inc. | 4 | $157 |
| Lilly USA, LLC | 9 | $126 |
| Amgen(2 entities) | 4 | $121 |
| Globus Medical | 1 | $110 |
| Abbott | 5 | $99 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $78 |
| Neurelis, Inc. | 3 | $56 |
| Novartis | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| GE HealthCare | 1 | $27 |
| Smith+Nephew | 1 | $27 |
| Lucid Diagnostics Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $20 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$1,368 in reported general payments places this provider in the 40th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 27 | $39,439 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $21,906 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $21,659 |
| Levetiracetam | 67 | $3,298 |
| Memantine Hcl | 66 | $2,909 |
| Sumatriptan Succinate | 30 | $2,272 |
| Gabapentin | 83 | $1,394 |
| Teriflunomide | 22 | $1,342 |
| Topiramate | 65 | $1,286 |
| Pyridostigmine Bromide | 12 | $1,257 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 67 | $1,249 |
| Divalproex Sodium ErDivalproex Sodium | 37 | $1,119 |
| Oxcarbazepine | 27 | $982 |
| RizatriptanRizatriptan Benzoate | 23 | $653 |
| Donepezil Hcl | 52 | $573 |
Paid to pharmacies, not to this prescriber.
Other neurology in Brandon
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.